Showing 5201-5210 of 5621 results for "".
- New CPT Code for Automated Point-of-Care Retinal Imaginghttps://modernod.com/news/new-cpt-code-for-automated-point-of-care-retinal-imaging/2476690/Artificial intelligence diagnostics company IDx announced that the American Medical Association (AMA) has accepted a new category 1 CPT code for automated point-of-care retinal imaging. This new code, submitted by the American Academy of Ophthalmology (AAO) with the support of IDx, facilitates co
- Alimera’s Iluvien Receives Positive NICE Recommendation for Noninfectious Posterior Uveitishttps://modernod.com/news/alimeras-iluvien-receives-positive-nice-recommendation-for-noninfectious-posterior-uveitis/2476675/Alimera Sciences announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE), in its Final Appraisal Determination for national reimbursement, has recommended funding for Iluvien 190 micrograms intravitreal implant in applicator for the prevention of relapse
- Bausch + Lomb Ultra Multifocal for Astigmatism Contact Lenses Now Available In the United Stateshttps://modernod.com/news/bausch-lomb-ultra-multifocal-for-astigmatism-contact-lenses-now-available-in-the-united-states/2476671/Bausch + Lomb announced the US launch of Bausch + Lomb Ultra Multifocal for Astigmatism contact lenses. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision n
- Harrow Health to Locate Headquarters in Nashville, Tennesseehttps://modernod.com/news/harrow-health-to-locate-headquarters-in-nashville-tennessee/2476667/Harrow Health announced that the company will relocate its headquarters from San Diego to Nashville, Tennessee. “From our new home in Nashville, our team will continue to start, finance and grow pharmaceutical companies that will develop innovative, affordable and accessible medicines to s
- Be The Match BioTherapies and TrakCel Partner to Standardize Cell and Gene Therapy Supply Chain Solutionshttps://modernod.com/news/be-the-match-biotherapies-and-trakcel-partner-to-standardize-cell-and-gene-therapy-supply-chain-solutions/2476662/Be The Match BioTherapies and TrakCel, a software developer for cell and gene therapy supply chain tracking and orchestration systems, announced a collaboration that will provide integrated solutions for companies develo
- Eyepromise Introduces Screen Shield Pro All-Natural Eye Vitamin for Screen Time Protection for Adultshttps://modernod.com/news/eyepromise-introduces-screen-shield-pro-all-natural-eye-vitamin-for-screen-time-protection-for-adults/2476661/EyePromise announced the introduction of Screen Shield Pro to its premium eye vitamin line. EyePromise’s Screen Shield Pro is designed to protect and relieve the associated symptoms of digital eye strain of adults (ages 18 and up) who spend 8+ hours staring at digital screens while working, gami
- Santen Publishes New Data in Glaucoma and Dry Eye Drug Candidateshttps://modernod.com/news/santen-publishes-new-data-in-glaucoma-and-dry-eye-drug-candidates/2476660/Santen EMEA shared the preliminary results of its two real world evidence (RWE) studies, VISIONARY and PERSPECTIVE, at this year’s European Society of Ophthalmology (SOE) congress. The studies assessed the impact of the effectiveness, tolerability, and safety of topical preservative-free taflupro
- Ribomic Announces Positive Topline Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-positive-topline-results-from-the-phase-1-2a-clinical-trial-of-rbm-007-sushi-study-in-subjects-with-wet-amd/2476656/Ribomic announced positive topline results from its SUSHI study, a phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet age-related macular degeneration (AMD). The SUSHI study achiev
- Amarantus Announces Issuance of US Patent Covering MANF Treatment of Wolfram’s Syndrome, Retinitis Pigmentosa, and Glaucomahttps://modernod.com/news/amarantus-announces-issuance-of-us-patent-covering-manf-treatment-of-wolframs-syndrome-retinitis-pigmentosa-and-glaucoma/2476653/Amarantus Bioscience Holdings announced that subsidiary MANF Therapeutics was issued US Patent No. 10,195,251 entitled “Methods of Treatment for Retinal Diseases Using MANF and CDNF” that covers the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) or cerebral dopamine
- Post-Approval Study Finds No Surprises With Argus II Retinal Implanthttps://modernod.com/news/post-approval-study-finds-no-surprises-with-argus-ii-retinal-implant/2476647/Post-approval follow-up of the Argus II Retinal Prosthesis System shows safety and visual function outcomes similar to those in previous trials, according to a company-funded study, as reported in Reuters. With a CE mark granted in 2011, the device became the first retinal prosthesis to b